Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 8/20 | 0.45 |
| ▸ | GAA | P10253 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27434077 | 0.90 | GFER (0.45) | GFERCA1CA2CA4CA7 | |
| SCHEMBL1123900 | 0.84 | GFER (0.50) | GFERCA1CA2CA4CA7 | |
| SCHEMBL20893356 | 0.81 | CA1 (0.53) | GFERCA1CA2CA4CA7 | |
| SCHEMBL519257 | 0.81 | MAPT (0.56) | GFERMAPTGAAMEN1KMT2A | |
| SCHEMBL3941339 | 0.81 | CA1 (0.53) | GFERCA1CA2CA4CA7 | |
| SCHEMBL3941336 | 0.81 | CA1 (0.53) | GFERCA1CA2CA4CA7 | |
| SCHEMBL19384292 | 0.79 | MAPT (0.50) | CA1CA2CA7MAPTGAA | |
| SCHEMBL7490755 | 0.78 | MAPT (0.54) | GFERMAPTGAAMEN1KMT2A | |
| SCHEMBL21283603 | 0.78 | MAPT (0.45) | GFERCA1CA2CA4CA7 | |
| SCHEMBL9068343 | 0.78 | CA1 (0.50) | GFERCA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309552-B2 | Immunomodulating heterocyclic compounds | MEDIGENE AG (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8309552-B2 | Immunomodulating heterocyclic compounds | MEDIGENE AG (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8309552-B2 | Immunomodulating heterocyclic compounds | MEDIGENE AG (DE) | 2012-11-13 | — | — | US | disclosed |
| EP-2284172-A1 | Immunomodulating heterocyclic compounds | MediGene Ltd. (GB) | 2011-02-16 | — | — | EP | disclosed |
| EP-2284172-A1 | Immunomodulating heterocyclic compounds | MediGene Ltd. (GB) | 2011-02-16 | — | — | EP | disclosed |
| EP-1603917-B1 | IMMUNOMODULATING HETEROCYCLIC COMPOUNDS | MEDIGENE LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| EP-1603917-B1 | IMMUNOMODULATING HETEROCYCLIC COMPOUNDS | MEDIGENE LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| WO-1994025445-A1 | 1,5-BENZODIAZEPINES USEFUL AS GASTRIN OR CCK-ANTAGONISTS | GLAXO S.P.A. (IT) | 1994-11-10 | — | — | WO | disclosed |
| WO-1994025444-A1 | 3-PHENYLUREIDO-1,5-BENZODIAZEPINE-DIONES USEFUL AS GASTRIN OR CCK ANTAGONISTS | GLAXO SPA (IT) | 1994-11-10 | — | — | WO | disclosed |
| EP-0623118-A1 | CARBAMATE DERIVATIVES AND THEIR USE IN MEDICINE | GLAXO S.p.A. (IT) | 1994-11-09 | — | — | EP | disclosed |
| WO-1994024149-A1 | 1,5-BENZODIAZEPINE DERIVATIVES HAVING CCK ANTAGONISTIC OR AGONISTIC ACTIVITY | GLAXO INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| WO-1994024151-A1 | 1,5 BENZODIAZEPINE DERIVATIVES HAVING CCK AND/OR GASTRIN ANTAGONISTIC ACTIVITY | GLAXO INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| CN-1077952-A | CARBAMATE DERIVATIVES | GLAXO SPA (IT) | 1993-11-03 | — | — | CN | disclosed |
| EP-0558104-A1 | 1,5-Benzodiazepine derivatives and their use in medicine | GLAXO S.p.A. (IT) | 1993-09-01 | — | — | EP | disclosed |
| WO-1993014074-A1 | 1,5-BENZODIAZEPINE DERIVATIVES AND THEIR USE IN MEDICINE | GLAXO SPA (IT) | 1993-07-22 | — | — | WO | disclosed |
| WO-1993014075-A1 | CARBAMATE DERIVATIVES AND THEIR USE IN MEDICINE | GLAXO SPA (IT) | 1993-07-22 | — | — | WO | disclosed |
| US-4495351-A | FOR UROGENVITAL DISORDERS | VEB ARZNEIMITTELWERK DRESDEN (DD) | 1985-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | GFER 1223/4885CA1 2084/4885CA2 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.